Trial Profile
Efficacy, tolerability, and post-marketing surveillance of omalizumab in patients with uncontrolled severe allergic asthma in Japan
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2018 Results published in the Respiratory Medicine
- 07 Aug 2014 New trial record
- 10 Sep 2013 Interim results presented at the 23rd Annual Congress of the European Respiratory Society.